April 11, 2001 — Troglitazone Improves Ovulation And Hirsutism In Women With Polycystic Ovary Syndrome

A new study, published in the April issue of the Journal of Clinical Endocrinology & Metabolism, shows that troglitazone, an insulin-sensitizing agent and member of the thiazolidinedione class of drugs, improves ovulation and hirsutism in women who suffer from Polycystic Ovary Syndrome (PCOS), an endocrine disorder that effects seven to 10 percent of reproductive-age women. This study is the first trial of its size that shows long term changes in ovulatory function in women with PCOS,” said Dr. Mahmoud Ghazzi, MD, PhD, a researcher and Senior Director of the Endocrine and Metabolism division at Pfizer Inc, (Parke-Davis, which funded the study, was a division of Warner- Lambert, which merged with Pfizer Inc in June 2000). “Additionally, this study is the first to show that using an insulin sensitizing agent results in improvement in hirsutism, which is often associated with PCOS.”

Leave a Comment